Citation Information :
Krishna G, Ravindran SK, Balu P, Muthu J, Sathiyaseelan S. Comparison of Sclerostin Levels in Gingival Crevicular Fluid before and after Nonsurgical Therapy in Smokers and Nonsmokers with Chronic Periodontitis. World J Dent 2021; 12 (5):363-366.
Aim and objective: This study aims to assess gingival crevicular fluid levels of sclerostin before and after nonsurgical periodontal therapy in smokers and nonsmokers with chronic generalized periodontitis.
Materials and methods: Subjects with generalized chronic periodontitis were divided into two groups: Group I—nonsmokers with chronic periodontitis (n = 18) and group II—smokers with chronic periodontitis (n = 18). Baseline clinical parameters were recorded and a GCF sample was collected for assessment of sclerostin levels. All the patients received nonsurgical periodontal therapy. GCF sampling and clinical periodontal measurements were repeated 4 weeks after completion of SRP. Sclerostin levels were analyzed using an enzyme-linked immunosorbent assay (HUMAN SOST ELISA KIT). The data were tested statistically by the Student\'s t-test: Intragroup analysis was done using paired t-test and intergroup was done using independent t-test.
Results: Probing pocket depth and clinical attachment loss were decreased significantly in both smokers and nonsmokers after nonsurgical therapy. The levels of sclerostin were higher in the smoker group when compared with nonsmokers. The mean sclerostin levels in smokers and nonsmokers at baseline were 354 ± 141 and 164.87 ± 59.8 pg/mL, respectively. There is a significant decrease in sclerostin levels from (164–136 pg/mL) in nonsmokers after nonsurgical therapy (p = 0.001).
Conclusion: Sclerostin levels were significantly higher in smokers when compared with nonsmokers at the baseline and exhibited persistent higher levels even after periodontal therapy in smokers.
Clinical significance: Sclerostin is an osteocyte secreted soluble antagonist of the wnt/β catenin signaling pathway which is a requisite for osteoblast development and osteogenesis. Increased sclerostin levels in smokers increase and hasten periodontal destruction. Therefore, sclerostin can be a promising therapeutic target for control of osteoclastic activity and promotion of osteogenesis in chronic periodontitis and more so in smokers.
Lamont RJ, Koo H, Hajishengallis G. The oral microbiota: dynamic communities and host interactions. Nat Rev Microbiol 2018;16(12):745–759. DOI: 10.1038/s41579-018-0089-x.
Graves DT, Oates T, Garlet GP. Review of osteoimmunology and the host response in endodontic and periodontal lesions. J Oral Microbiol 2011;3(1):5304. DOI: 10.3402/jom.v3i0.5304.
Phan TC, Xu J, Zheng MH. Interaction between osteoblast and osteoclast: impact in bone disease. Histol Histopathol 2004;19(4):1325–1344. DOI: 10.14670/HH-19.1325.
Kim JH, Liu X, Wang J, et al. Wnt signaling in bone formation and its therapeutic potential for bone diseases. Ther Adv Musculoskelet Dis 2013;5(1):13–31. DOI: 10.1177/1759720X12466608.
Baron R, Rawadi G. Targeting the Wnt/beta-catenin pathway to regulate bone formation in the adult skeleton. Endocrinology 2007;148(6):2635–2643. DOI: 10.1210/en.2007-0270.
Rezaei Esfahrood Z, Yadegari Z, Veysari SK, et al. Gingival crevicular fluid levels of sclerostin in chronic periodontitis and healthy subjects. J Korean Assoc Oral Maxillofac Surg 2018;44(6):289–292. DOI: 10.5125/jkaoms.2018.44.6.289.
Balli U, Aydogdu A, Dede FO, et al. Gingival crevicular fluid levels of sclerostin, osteoprotegerin, and receptor activator of nuclear factor-κB ligand in periodontitis. J Periodontol 2015;86(12):1396–1404. DOI: 10.1902/jop.2015.150270.
Miranda TS, Napimoga MH, Feres M, et al. Antagonists of Wnt/β-catenin signalling in the periodontitis associated with type 2 diabetes and smoking. J Clin Periodontol 2018;45(3):293–302. DOI: 10.1111/jcpe.12854.
Ana P, Obradovic R, Ljiljana K, et al. Smoking and periodontal disease: a review. Med Biol 2007;14:53–59.
Darby IB, Hodge PJ, Riggio MP, et al. Clinical and microbiological effect of scaling and root planing in smoker and non-smoker chronic and aggressive periodontitis patients. J Clin Periodontol 2005;32(2):200–206. DOI: 10.1111/j.1600-051X.2005.00644.x.
Farina R, Simonelli A, Rizzi A, et al. Effect of smoking status on pocket probing depth and bleeding on probing following non-surgical periodontal therapy. Minerva Stomatol 2010;59(1-2):1–12. English, Italian.
Chang J, Meng HW, Lalla E, et al. The impact of smoking on non-surgical periodontal therapy: a systematic review and meta-analysis. J Clin Periodontol 2021;48(1):60–75. DOI: 10.1111/jcpe.13384.
César Neto JB, Rosa EF, Pannuti CM, et al. Smoking and periodontal tissues: a review. Braz Oral Res 2012;26(Suppl 1):25–31. DOI: 10.1590/s1806-83242012000700005.
Johnson GK, Guthmiller JM. The impact of cigarette smoking on periodontal disease and treatment. Periodontol 2000 2007;44(1):178–194. DOI: 10.1111/j.1600-0757.2007.00212.x.
Chatzopoulos GS, Mansky KC, Lunos S, et al. Sclerostin and WNT-5a gingival protein levels in chronic periodontitis and health. J Periodontal Res 2019;54(5):555–565. DOI: 10.1111/jre. 12659.
García-Martín A, Rozas-Moreno P, Reyes-García R, et al. Circulating levels of sclerostin are increased in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2012;97(1):234–241. DOI: 10.1210/jc.2011-2186.
Napimoga MH, Nametala C, da Silva FL, et al. Involvement of the Wnt-β-catenin signalling antagonists, sclerostin and dickkopf-related protein 1, in chronic periodontitis. J Clin Periodontol 2014;41(6):550–557. DOI: 10.1111/jcpe.12245.
Yakar N, Guncu GN, Akman AC, et al. Evaluation of gingival crevicular fluid and peri-implant crevicular fluid levels of sclerostin, TWEAK, RANKL and OPG. Cytokine 2019;113:433–439. DOI: 10.1016/j.cyto.2018.10.021.